Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Objectives This study aims to study the association between socioeconomic factors and risk of prevalent eye diseases, ...

although Roche recently filed for approval of a third indication – retinal vein occlusion (RVO) – which could open a new area of competition with Eylea and add to its sales momentum if approved.

and retinal vascular occlusion (RO) were around twice as common with monthly Beovu injections compared to Eylea, which both target VEGF. Moreover, almost three times as many patients recorded ...

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year ...

Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in patients with neovascular ... and neovascularization of the retinal and ...